DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

478 BIBLIOGRAPHY
SECTION II
NEUROPHARMACOLOGY
Amakye DD, Hibberd M, Stevenson SJ. A phase I study to investigate
the absolute bioavailability of a single oral dose of
ramelteon (TAK-375) in healthy male subjects. Sleep, 2004,
27(Abstract Suppl):A54.
Amin J, Weiss DS. GABA A
receptor needs two homologous
domains of the β-subunit for activation by GABA but not by
pentobarbital. Nature, 1993, 366:565–569.
Balter MB, Uhlenhuth EH. New epidemiologic findings about
insomnia and its treatment. J Clin Psychiatry, 1992,
53(Suppl):34–39.
Burt DR. Reducing GABA receptors. Life Sci, 2003, 73:1741–1758.
Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E. Tolerance
and withdrawal with zolpidem. Lancet, 1993, 342:374–375.
Dell RG, Cloote AH. Patient-controlled sedation during transvaginal
oocyte retrieval: An assessment of patient acceptance
of patient-controlled sedation using a mixture of propofol and
alfentanil. Eur J Anaesthesiol, 1998, 15:210–215.
Dement WC. Objective measurements of daytime sleepiness and
performance comparing quazepam with flurazepam in two
adult populations using the Multiple Sleep Latency Test. J Clin
Psychiatry, 1991, 52(Suppl):31–37.
Dooley M, Plosker GL. Zaleplon: A review of its use in the treatment
of insomnia. Drugs, 2000, 60:413–445.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic–pharmacodynamic
consequences and clinical relevance of
cytochrome P450 3A4 inhibition. Clin Pharmacokinet, 2000,
38:41–57.
Dujardin K, Guieu JD, Leconte-Lambert C, et al. Comparison
of the effects of zolpidem and flunitrazepam on sleep structure
and daytime cognitive functions: A study of untreated
insomniacs. Pharmacopsychiatry, 1998, 31:14–18.
Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and
dose response study of ramelteon in patients with chronic primary
insomnia. Sleep Med, 2006, 7:17–24.
Essrich C, Lorez M, Benson JA, et al. Postsynaptic clustering of
major GABA A
receptor subtypes requires the γ2 subunit and
gephyrin. Nature Neurosci, 1998, 1:563–571.
File SE. Tolerance to the behavioral actions of benzodiazepines.
Neurosci Biobehav Rev, 1985, 9:113–121.
Fleming JA. The difficult to treat insomniac patient. J Psychosom
Res, 1993, 37(Suppl 1):45–54.
France CP, Weltman RH, Koek W, et al. Acute and chronic effects
of ramelteon in rhesus monkeys (macaca mulatta): Dependence
liability studies. Behav Neurosci, 2006, 120:535–541.
ffrench-Mullen JM, Barker JL, Rogawski MA. Calcium current
block by (–)-pentobarbital, phenobarbital, and CHEB but not
(+)-pentobarbital in acutely isolated hippocampal CA1 neurons:
Comparison with effects on GABA-activated Cl – current.
J Neurosci, 1993, 13:3211–3221.
Frenkel C, Duch DS, Urban BW. Molecular actions of pentobarbital
isomers on sodium channels from human brain cortex.
Anesthesiology, 1990, 72:640–649.
Garnier R, Guerault E, Muzard D, et al. Acute zolpidem poisoning—
analysis of 344 cases. J Toxicol Clin Toxicol, 1994, 32:
391–404.
Gary NE, Tresznewsky O. Clinical aspects of drug intoxication:
Barbiturates and a potpourri of other sedatives, hypnotics, and
tranquilizers. Heart Lung, 1983, 12:122–127.
Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: A
critical review. J Clin Psychopharmacol, 1989, 9:161–172.
Greenblatt DJ. Benzodiazepine hypnotics: Sorting the pharmacokinetic
facts. J Clin Psychiatry, 1991, 52(Suppl):4–10.
Griffiths RR, Johnson MW. Relative abuse liability of hypnotic
drugs: A conceptual framework and algorithm for differentiating
among compounds. J Clin Psychiatry, 2005, 66(Suppl 9):
31–41.
Griffiths RR, Sannerud CA, Ator NA, Brady JV. Zolpidem
behavioral pharmacology in baboons: Self-injection, discrimination,
tolerance and withdrawal. J Pharmacol Exp Ther,
1992, 260:1199–1208.
Guglielminotti J, Maury E, Alzieu M, et al. Prolonged sedation
requiring mechanical ventilation and continuous flumazenil
infusion after routine doses of clonazepam for alcohol withdrawal
syndrome. Intensive Care Med, 1999, 25:1435–1436.
Hanson SM, Morlock EV, Satyshur KA, et al. Structural requirements
for eszopiclone and zolpidem binding to the gammaaminobutyric
acid type-A (GABA A
) receptor are different.
J Med Chem, 2008, 51:7243–7252.
Herrmann WM, Kubicki ST, Boden S, et al. Pilot controlled, double-blind
study of the hypnotic effects of zolpidem in patients
with chronic “learned” insomnia: Psychometric and polysomnographic
evaluation. J Int Med Res, 1993, 21: 306–322.
Heuss LT, Inauen W. The dawning of a new sedative: Propofol in
gastrointestinal endoscopy. Digestion, 2004, 69:20–26.
Hibberd M, Stevenson SJ. A phase-I open-label study of the
absorption, metabolism, and excretion of (14C)-ramelteon
(TAK-375) following a single oral dose in healthy male subjects.
Sleep, 2004, 27(Abstract Suppl):A54
Hindmarch I, Fairweather DB, Rombaut N. Adverse events after
triazolam substitution. Lancet, 1993, 341:55.
Hoffman, E.J., and Warren, E.W. Flumazenil: A benzodiazepine
antagonist. Clin Pharmacol, 1993, 12:641–656.
Holm KJ, Goa KL. Zolpidem: An update of its pharmacology,
therapeutic efficacy and tolerability in the treatment of insomnia.
Drugs, 2000, 59:865–889.
James I, Savage I. Beneficial effect of nadolol on anxietyinduced
disturbances of performance in musicians: A comparison
with diazepam and placebo. Am Heart J, 1984, 108:
1150–1155.
Jia F, Goldstein PA, Harrison NL.The modulation of synaptic
GABA A
receptors in the thalamus by eszopiclone and zolpidem.
J Pharmacol Exp Ther, 2009, 328:1000–1006.
Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW.
Comparative clinical profiles of triazolam versus other shorteracting
hypnotics. J Clin Psychiatry, 1992, 53(Suppl):19–31.
Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties
of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Neuropharmacology, 2005, 48:301–310.
Kleingoor C, Wieland HA, Korpi ER, et al. Current potentiation
by diazepam but not GABA sensitivity is determined by a single
histidine residue. Neuroreport, 1993, 4:187–190.
Kriel RL, Cloyd JC, Pellock JM. Respiratory depression in children
receiving diazepam for acute seizures: A prospective
study. Dev Med Child Neurol, 2000, 42:429–430.
Kummer J, Guendel L, Linden J, et al. Long-term polysomnographic
study of the efficacy and safety of zolpidem in elderly
psychiatric in-patients with insomnia. J Int Med Res, 1993,
21:171–184.